CAN-3110 is a first-in-class herpes simplex virus-1 oncolytic immunotherapy candidate with dual activity for oncolysis and immune activation in a single therapeuticIn a first-in-human clinical trial of CAN-3110 in recurrent high-grade glioma, CAN-3110 was well tolerated and treatment was associate with improved survivalPositive HSV-1 serology, before or after CAN-3110 injection, was a predictor of response and was associated with improved survivalIncreased infiltrating immune cells in the tumor microenvironment and expansion of the T cell repertoire after treatment were associated with improved survival NEEDHAM, Mass., Oct.

CAN-3110是一流的单纯疱疹病毒-1溶瘤免疫治疗候选药物，在单一疗法中具有双重溶瘤和免疫激活活性在CAN-3110复发性高级别胶质瘤的首次人体临床试验中，CAN-3110在CAN-3110注射之前或之后，耐受性良好并且治疗与改善的存活阳性HSV-1血清学相关，是反应的预测因子，并且与肿瘤微环境中存活增加的浸润性免疫细胞的改善相关，并且治疗后T细胞库的扩增与改善的存活NEEDHAM，Mass。，Oct相关。

18, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (the Company or Candel) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Nature published results from the ongoing first-in-human phase 1 investigator-sponsored clinical trial of CAN-3110, a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate, in patients with recurrent high-grade glioma (HGG), of which 86.7% were glioblastoma, that had returned after standard of care (SoC) treatment.

182023（GLOBE NEWSWIRE）-Candel Therapeutics，Inc。（公司或坎德尔）（纳斯达克股票代码：CADL），一家专注于开发病毒免疫疗法以帮助患者对抗癌症的临床阶段生物制药公司，今天宣布Nature公布了结果来自正在进行的首次人体1期研究者赞助的CAN-3110临床试验，一流，复制型单纯疱疹病毒-1（HSV-1）溶瘤病毒免疫治疗候选者，复发性高级别胶质瘤（HGG）患者，其中86.7%为胶质母细胞瘤，在标准治疗（SoC）治疗后恢复。

The study is being conducted in a collaboration between Brigham and Women’s Hospital and Candel. The publication titled “Clinical trial links oncolytic immunoactivation to survival in glioblastoma” can be accessed here. Key findings of the manuscript: Tolerability of a single injection of CAN-3110 in recurrent HGG with no dose limiting toxicity reported, improved median overall survival in 41 patients treated in Arm A (11.6 months as of data cutoff in October 2022) and correlation between anti-HSV-1 serology and survival.

这项研究是在布里格姆妇女医院和蜡烛之间合作进行的。可以在这里访问标题为“临床试验将溶瘤免疫激活与胶质母细胞瘤的存活联系起来”的出版物。手稿的主要发现：单次注射CAN-3110对复发性HGG的耐受性，未报告剂量限制性毒性，改善了a组41例患者的中位总生存期（截至2022年10月数据截止时为11.6个月）和相关性抗HSV-1血清学与生存期之间的关系。

Importantly, CAN-3110 treatment .

重要的是，CAN-3110治疗。